Amisulpride (CAS 71675-85-9)
QUICK LINKS
Amisulpride is a compound used in research models to explore its interaction with dopamine receptors and the resulting effects on neurotransmitter pathways. In neurochemical studies, amisulpride is known for its high affinity for D2 and D3 dopamine receptor subtypes. Research involving amisulpride focuses on understanding the modulation of dopaminergic systems, which are implicated in regulating mood, motivation, and reward processes. In certain models, amisulpride is used to investigate the effects of altered dopamine receptor activity on behavior and to model conditions where dopamine modulation is a key factor. Furthermore, amisulpride is applied in receptor binding assays to quantify the presence and density of dopamine receptors in various tissues. Its selectivity for dopaminergic receptors makes it useful for dissecting the roles of specific receptor subtypes in physiological and pathological processes within the central nervous system.
Amisulpride (CAS 71675-85-9) References
- Amisulpride promotes cognitive flexibility in rats: the role of 5-HT7 receptors. | Nikiforuk, A. and Popik, P. 2013. Behav Brain Res. 248: 136-40. PMID: 23603557
- Amisulpride as add-on treatment for resistant obsessive-compulsive disorder: retrospective case series. | Miodownik, C., et al. 2015. Clin Neuropharmacol. 38: 26-9. PMID: 25580923
- Amisulpride: A New Dopamine Antagonist for Treatment of Postoperative Nausea and Vomiting. | Gan, TJ. and Mouch, CM. 2019. Anesth Analg. 128: 1074-1076. PMID: 31094771
- Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses. | Glatard, A., et al. 2020. Clin Pharmacokinet. 59: 371-382. PMID: 31552612
- Microenvironmental pH-modified Amisulpride-Labrasol matrix tablets: development, optimization and in vivo pharmacokinetic study. | Younes, NF., et al. 2021. Drug Deliv Transl Res. 11: 103-117. PMID: 31900797
- Efficacy of amisulpride on postoperative nausea and vomiting: a systematic review and meta-analysis. | Zhang, LF., et al. 2020. Eur J Clin Pharmacol. 76: 903-912. PMID: 32274525
- Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China. | Yi, ZM., et al. 2020. Expert Rev Pharmacoecon Outcomes Res. 20: 313-320. PMID: 32293194
- Amisulpride alleviates chronic mild stress-induced cognitive deficits: Role of prefrontal cortex microglia and Wnt/β-catenin pathway. | Mohamed, AM., et al. 2020. Eur J Pharmacol. 885: 173411. PMID: 32800810
- Occurrence of macroprolactinemia in schizophrenia patients treated with risperidone or amisulpride. | Zhenhua, W., et al. 2022. Asia Pac Psychiatry. 14: e12469. PMID: 33754473
- Amisulpride: A Useful Second-Generation Antipsychotic Omitted From the US Residency Training Curriculum. | Gupta, M. 2021. Prim Care Companion CNS Disord. 23: PMID: 34738352
- Amisulpride withdrawal akathisia responding to aripiprazole with propranolol in first-onset psychosis: a case report. | Yang, HJ., et al. 2022. BMC Psychiatry. 22: 74. PMID: 35093063
- When to Use Amisulpride in Adolescents: A Retrospective Chart Examination of Inpatients. | Tuncturk, M., et al. J Clin Psychopharmacol. 42: 247-253. PMID: 35149609
- Amisulpride steady-state plasma concentration and adverse reactions in patients with schizophrenia: a study based on therapeutic drug monitoring data. | Qu, K., et al. 2022. Int Clin Psychopharmacol. 37: 255-262. PMID: 35779068
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Amisulpride, 50 mg | sc-203510 | 50 mg | $116.00 |